Hepatitis B Vaccinations Accelerate in Pharmacies

Dynavax Technologies Corporation today announced that HEPLISAV-B® vaccine net product revenue grew 10% year-over-year to approximately $48 million in the first quarter of 2024.

HEPLISAV-B is the first and only adult hepatitis B vaccine approved in the U.S., the European Union, and Great Britain to enable series completion with only two doses in one month.

In 2024, HEPLISAV-B's total estimated market share in the U.S. increased to approximately 41%, and its estimated market share in the retail pharmacy segment increased to approximately 55%.

"The U.S. adult hepatitis B vaccine opportunity remains significant with over 130 million patients eligible, one of the largest addressable patient populations in the U.S., and the vast majority remaining unvaccinated," said Ryan Spencer, Chief Executive Officer of Dynavax in a press release on May 8, 2024.

Hepatitis B is a viral infection that affects the liver and can cause acute or chronic disease.

Driven by the U.S. CDC's Advisory Committee of Immunization Practices' universal recommendation for adult hepatitis B vaccination, the hepatitis B vaccine market continues to expand in the U.S. Dynavax believes the U.S. market has the potential to grow to over $800 million by 2027, with HEPLISAV-B well-positioned to achieve a majority market share.

A supplemental Biologic License Application for HEPLISAV-B vaccination of adults on hemodialysis is currently under review by the U.S. FDA, with a Prescription Drug User Fee Act action date planned for May 13, 2024.